KRAS and lung carcinoma: Interestingly, knockdown of IKKα in the lung cancer cells studied not only reduced NF-κB activity (Supplementary Fig. S1), but more importantly, inhibition of KRAS, IKKβ or IKKα by siRNA in H358 cells inhibited IκBα phosphorylation and degradation, a hallmark of the canonical NF-κB activation pathway (Fig. 1C).